Name (Synonyms) | Correlation | |
---|---|---|
drug2830 | Talabostat Mesylate plus Pembrolizumab Wiki | 1.00 |
drug759 | Convalescent Plasma of patients with COVID-19 Wiki | 1.00 |
drug3409 | placebo (hartmann plus albumine) Wiki | 1.00 |
Name (Synonyms) | Correlation | |
---|---|---|
D055752 | Small Cell Lung Carcinoma NIH | 1.00 |
D018288 | Carcinoma, Small Cell NIH | 1.00 |
D018358 | Neuroendocrine Tumors NIH | 0.58 |
D011471 | Prostatic Neoplasms NIH | 0.50 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0100634 | Neuroendocrine neoplasm HPO | 0.58 |
HP:0012125 | Prostate cancer HPO | 0.50 |
There is one clinical trial.
An open-label, multicenter, Phase 1b/2 study to determine the composite response rate of BXCL701 administered orally and daily, combined wit PEMBRO, in patients with mCRPC enrolled in Stage 2, with either Small Cell Neuroendocrine Prostate Cancer(SCNC)(Cohort A) or adenocarcinoma phenotype (Cohort B). This study will also assess other efficacy parameters as well as the safety of the combined treatment. This study will consist of two (2) stages. Lead-in Stage, in which the safety and tolerability of the combination will be assessed and confirmed. And the Efficacy Stage, in which patients will be treated with BXCL701 combined with PEMBRO.
Description: Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria; circulating tumor cell (CTC) conversion from >5/7.5 mL to <5/7.5 mL12; and a greater than 50% prostate-specific antigen (PSA) decline from baseline.
Measure: Estimate the composite response rate of the combination of BXCL701 + PEMBRO Time: up to 36 monthsDescription: The median time frame with progression-free survival with the use of BXCL701 in combination with Pembro determined by radiographic evidence.
Measure: Estimate the median radiographic progression-free survival (rPFS) of the combination of BXCL701 and PEMBRO in Cohort A and B Time: up to 36 monthsDescription: The median time frame with progression-free survival with the use of BXCL701 in combination with Pembro
Measure: Estimate the median PSA progression-free survival (PSA PFS) of the combination of BXCL701 and PEMBRO in Cohort A and B. Time: up to 36 monthsDescription: The median time frame with overall survival with the use of BXCL701 in combination with Pembro
Measure: Estimate the median overall survival (OS) of the combination of BXCL701 and PEMBRO in Cohort A and B. Time: up to 36 monthsDescription: The timeframe in which the tumor reacts to BXCL701 in combination with Pembro
Measure: Estimate the median duration of response (DOR) of the combination of BXCL701 and PEMBRO in Cohort A and B. Time: up to 36 monthsDescription: Determines the frequency and severity of known and unknown adverse events with the use of BXCL701 in combination with Pembro
Measure: Determine the risk profile of the use of BXCL701 in combination with PEMBRO. Time: up to 36 months